Taiho Pharmaceutical Co, Ltd. announces that it and Astex Pharmaceuticals (UK), both Otsuka group companies, have granted an exclusive licence under their joint, small-molecule drug discovery programme targeting SHP2, to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada through a subsidiary.
Astex Pharmaceuticals welcomes positive, new data showing breast cancer drug, Kisqali® (ribociclib), cuts risk of death by up to a third when given with hormone therapy.
Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML).
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti PhD, co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been elected a Fellow of the Royal Society in recognition of his outstanding contribution to drug…
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced that its pharmaceutical collaborator, Janssen Pharmaceutica NV has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.
The Dementia Consortium, a unique charity-private partnership, today announced Astex Pharmaceuticals as a new member.
Cancer Research UK's Drug Development Office (DDO) has announced that Astex Pharmaceuticals will join its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance with an aim to develop new cancer treatments.